{"id":100042,"date":"2023-09-11T13:45:03","date_gmt":"2023-09-11T13:45:03","guid":{"rendered":"https:\/\/dailytalks.org\/?p=100042"},"modified":"2023-09-11T13:45:03","modified_gmt":"2023-09-11T13:45:03","slug":"nubeqa-darolutamide-receives-eu-approval-for-additional-indication-in-prostate-cancer","status":"publish","type":"post","link":"https:\/\/dailytalks.org\/?p=100042","title":{"rendered":"Nubeqa&#x2122; (darolutamide) receives EU approval for additional indication in prostate cancer"},"content":{"rendered":"<p>Berlin, March 1, 2023 \u2013 The European Commission has granted marketing authorization in the European Union (EU) for Nubeqa&#x2122; (darolutamide), an oral androgen receptor inhibitor (ARi), plus androgen deprivation therapy (ADT) in combination with docetaxel, for the treatment of patients with metastatic hormone-sensitive prostate cancer (mHSPC&#8230;<br \/><a href=\"https:\/\/www.bayer.com\/media\/en-us\/nubeqa-darolutamide-receives-eu-approval-for-additional-indication-in-prostate-cancer\/\" class=\"button purchase\" rel=\"nofollow noopener\" target=\"_blank\">Read More<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Berlin, March 1, 2023 \u2013 The European Commission has granted marketing authorization in the European<\/p>\n","protected":false},"author":1,"featured_media":100043,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[16],"tags":[],"class_list":["post-100042","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-europe"],"featured_image_urls":{"full":["https:\/\/dailytalks.org\/wp-content\/uploads\/2023\/09\/100042-nubeqa-darolutamide-receives-eu-approval-for-additional-indication-in-prostate-cancer.jpg",1200,630,false],"thumbnail":["https:\/\/dailytalks.org\/wp-content\/uploads\/2023\/09\/100042-nubeqa-darolutamide-receives-eu-approval-for-additional-indication-in-prostate-cancer-150x150.jpg",150,150,true],"medium":["https:\/\/dailytalks.org\/wp-content\/uploads\/2023\/09\/100042-nubeqa-darolutamide-receives-eu-approval-for-additional-indication-in-prostate-cancer-300x158.jpg",300,158,true],"medium_large":["https:\/\/dailytalks.org\/wp-content\/uploads\/2023\/09\/100042-nubeqa-darolutamide-receives-eu-approval-for-additional-indication-in-prostate-cancer-768x403.jpg",640,336,true],"large":["https:\/\/dailytalks.org\/wp-content\/uploads\/2023\/09\/100042-nubeqa-darolutamide-receives-eu-approval-for-additional-indication-in-prostate-cancer-1024x538.jpg",640,336,true],"1536x1536":["https:\/\/dailytalks.org\/wp-content\/uploads\/2023\/09\/100042-nubeqa-darolutamide-receives-eu-approval-for-additional-indication-in-prostate-cancer.jpg",1200,630,false],"2048x2048":["https:\/\/dailytalks.org\/wp-content\/uploads\/2023\/09\/100042-nubeqa-darolutamide-receives-eu-approval-for-additional-indication-in-prostate-cancer.jpg",1200,630,false],"chromenews-featured":["https:\/\/dailytalks.org\/wp-content\/uploads\/2023\/09\/100042-nubeqa-darolutamide-receives-eu-approval-for-additional-indication-in-prostate-cancer-1024x538.jpg",1024,538,true],"chromenews-large":["https:\/\/dailytalks.org\/wp-content\/uploads\/2023\/09\/100042-nubeqa-darolutamide-receives-eu-approval-for-additional-indication-in-prostate-cancer-825x575.jpg",825,575,true],"chromenews-medium":["https:\/\/dailytalks.org\/wp-content\/uploads\/2023\/09\/100042-nubeqa-darolutamide-receives-eu-approval-for-additional-indication-in-prostate-cancer-590x410.jpg",590,410,true]},"author_info":{"display_name":"Jonathan Jeriah","author_link":"https:\/\/dailytalks.org\/?author=1"},"category_info":"<a href=\"https:\/\/dailytalks.org\/?cat=16\" rel=\"category\">Europe<\/a>","tag_info":"Europe","comment_count":"0","_links":{"self":[{"href":"https:\/\/dailytalks.org\/index.php?rest_route=\/wp\/v2\/posts\/100042","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/dailytalks.org\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/dailytalks.org\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/dailytalks.org\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/dailytalks.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=100042"}],"version-history":[{"count":0,"href":"https:\/\/dailytalks.org\/index.php?rest_route=\/wp\/v2\/posts\/100042\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/dailytalks.org\/index.php?rest_route=\/wp\/v2\/media\/100043"}],"wp:attachment":[{"href":"https:\/\/dailytalks.org\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=100042"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/dailytalks.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=100042"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/dailytalks.org\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=100042"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}